AIM ImmunoTech Announces Prelim. Data From Phase 1b/2 Study Of Ampligen And Imfinzi; Says 'Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort'
Portfolio Pulse from Benzinga Newsdesk
AIM ImmunoTech has announced preliminary data from its Phase 1b/2 study of Ampligen in combination with Imfinzi. The study shows stable disease in two out of three patients at 6 months in the first subject cohort.
September 19, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AIM ImmunoTech's preliminary data from its study of Ampligen with Imfinzi shows stable disease in two out of three patients, which could positively impact investor sentiment.
The preliminary data indicating stable disease in a majority of patients is a positive sign for the efficacy of AIM's treatment, likely boosting investor confidence and potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100